Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368810 | 1.00 | GPR119 (0.44) | GPR119KITKCNH2MAP4K4EGLN2 | |
| SCHEMBL22788420 | 1.00 | GPR119 (0.44) | GPR119KITKCNH2MAP4K4EGLN2 | |
| SCHEMBL17634043 | 0.88 | GPR119 (0.44) | GPR119KITKCNH2MAP4K4EGLN2 | |
| SCHEMBL19294663 | 0.88 | GPR119 (0.44) | GPR119KITKCNH2MAP4K4EGLN2 | |
| SCHEMBL16784372 | 0.86 | KIT (0.47) | GPR119KITKCNH2MAP4K4CNR1 | |
| SCHEMBL17634059 | 0.85 | AKT1 (0.36) | KITMAPT | |
| SCHEMBL16784431 | 0.84 | KIT (0.46) | GPR119KITKCNH2MAP4K4CNR1 | |
| SCHEMBL16784360 | 0.79 | KIT (0.47) | GPR119KITMAP4K4CNR1CNR2 | |
| SCHEMBL16624819 | 0.75 | KIT (0.46) | GPR119KITMAP4K4CNR1CNR2 | |
| SCHEMBL18950223 | 0.74 | KIT (0.48) | GPR119KITMAP4K4CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112062727-B | Process for the preparation of (cyclopenta [ d ] pyrimidin-4-yl) piperazine compounds | 豪夫迈·罗氏有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230122620-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2021254920-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| US-10870626-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2020-12-22 | — | — | US | disclosed |
| CN-112062727-A | Process for preparing (cyclopenta [ d ] pyrimidin-4-yl) piperazine compounds | 豪夫迈·罗氏有限公司 | 2020-12-11 | — | — | CN | disclosed |
| CN-107001287-B | Process for preparing (cyclopenta [ d ] pyrimidin-4-yl) piperazine compounds | 豪夫迈·罗氏有限公司 | 2020-09-04 | — | — | CN | disclosed |
| US-10457648-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | GENENTECH INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3197875-B1 | PROCESSES FOR PREPARING (CYCLOPENTYL[D]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2019-08-14 | — | — | EP | disclosed |
| US-20170247338-A1 | PROCESS FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2017-08-31 | — | — | US | disclosed |
| US-20170247338-A1 | PROCESS FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2017-08-31 | — | — | US | disclosed |
| WO-2016049414-A1 | PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870626-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | PAK5, CDK5, PPIP5K2 | GPR119 2698/4885KIT 428/4885KCNH2 3082/4885 |
| US-20230122620-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | DHPS, DPYD, TNKS | GPR119 3384/4885KIT 879/4885KCNH2 3729/4885 |
| US-20170247338-A1 | PROCESS FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | PAK5, CDK5, PPIP5K2 | GPR119 2698/4885KIT 428/4885KCNH2 3082/4885 |
| US-10457648-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | PAK5, CDK5, PPIP5K2 | GPR119 2698/4885KIT 428/4885KCNH2 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.